文献速递甲状腺疾病

细胞学不确定且分子检测阴性的甲状腺结节:恶性患病率与监测实践模式

Thyroid Nodules with Indeterminate Cytology and Negative Molecular Profile: Prevalence of Malignancy and Practice Paradigms for Surveillance.
PubMed 文献 · Thyroid · 2025-01-28

这项回顾性研究纳入2017年11月至2022年3月在本医疗系统行细针穿刺、Bethesda III或IV类且ThyroSeq v3检测为阴性、目前阴性或阴性但有限的556个结节。分子良性结节恶性患病率按所有结节与手术切除结节计算分别为3%至23%,Bethesda IV高于III;90%结节非手术管理,63%至少接受一次超声监测。作者认为阴性亚型应纳入临床管理建议,阴性但有限样本应重复穿刺,监测超声推荐用于TSN和TSCN结节。

要点

  • 分子良性Bethesda III和IV结节恶性患病率依所有结节与切除结节计算为3%至23%。
  • Bethesda IV分子良性结节恶性患病率高于III(低估算7.3% vs 1.6%,p<0.001;高估算48% vs 13%,p=0.0013)。
  • 非手术管理的结节中63%至少有一次监测超声,仅7%重复细针穿刺。

核心结论

  • ThyroSeq v3阴性亚型应纳入临床管理建议,阴性但有限样本应重复细针穿刺。
  • 未切除的阴性和目前阴性结节的最佳监测策略仍未知。
  • 在更多真实世界数据可用前,推荐对TSN和TSCN结节进行监测超声,类似ATA指南对Bethesda II类结节的建议。

研究设计与样本

  • 回顾性研究,纳入2017年11月至2022年3月在本医疗系统行细针穿刺活检、Bethesda III和IV类细胞学且ThyroSeq v3结果为阴性、目前阴性或阴性但有限的患者结节。
  • 共556个结节;记录切除结节的手术病理及超声监测实践细节。
  • 恶性患病率按所有结节(低估算)和手术切除结节(高估算)计算。

主要发现

  • ThyroSeq v3结果分布为443个(80%)阴性、85个(15%)目前阴性、28个(5%)阴性但有限。
  • 75个结节被切除:54个(9.7%)立即手术,21个(3.8%)监测影像后延迟手术。
  • 目前阴性和阴性但有限结节较阴性结节更可能立即手术切除(分别为20%、18%和7%,p<0.001)。
  • 分子良性Bethesda III和IV甲状腺结节恶性患病率依所有结节与切除结节计算在3%至23%之间。
  • Bethesda IV分子良性结节恶性患病率高于III(低估算7.3% vs 1.6%,p<0.001;高估算48% vs 13%,p=0.0013)。

关键数值与推荐

  • ThyroSeq v3阴性亚型应纳入临床管理建议。
  • 阴性但有限样本应重复细针穿刺。
  • 监测超声推荐用于TSN和TSCN结节,类似ATA指南对Bethesda II类结节的建议。

临床怎么用

  • 作者认为ThyroSeq v3阴性亚型应纳入临床管理建议,阴性但有限样本应重复细针穿刺。
  • 作者推荐对TSN和TSCN结节进行监测超声,类似ATA指南对Bethesda II类结节的建议。
  • 未切除的阴性和目前阴性结节的最佳监测策略仍未知。

局限性

  • 未切除的阴性和目前阴性结节的最佳监测策略仍未知。
  • 在更多真实世界数据可用前,监测超声推荐基于类似ATA指南对Bethesda II类结节的建议。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: In the era of molecular testing, thyroid nodules with indeterminate cytology are increasingly being managed nonoperatively. The false-negative rates of these molecular tests, and therefore missed malignancies, are not well defined in real-world clinical practice. Methods: This retrospective study of patients undergoing fine needle aspiration (FNA) biopsy at our health system between November 2017 and March 2022 included nodules with The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) III and IV cytology and negative, currently negative, or negative but limited ThyroSeq version 3 (TSv3) results. Surgical pathology of resected nodules, as well as details of ultrasound (US) surveillance practices, was recorded. A range of prevalence of malignancy (PoM) estimates were calculated based on all nodules (PoM low) and surgically resected nodules (PoM high). Results: The study cohort consisted of 556 nodules. TSv3 results were distributed as 443 (80%) negative, 85 (15%) currently negative, and 28 (5%) negative but limited. Overall, 75 nodules were resected: 54 nodules (9.7%) had immediate surgery, and 21 nodules (3.8%) had delayed surgery after surveillance imaging. Currently negative and negative but limited nodules were more likely to undergo immediate surgical resection compared with negative nodules (20%, 18%, and 7%, respectively, p < 0.001). The PoM in molecularly benign TBSRTC III and IV thyroid nodules ranged between 3% and 23% depending on the inclusion of all versus resected nodules. TBSRTC IV molecularly benign nodules had a higher PoM than TBSRTC III (PoM low 7.3% vs. 1.6%, p < 0.001; PoM high 48% vs. 13%, p = 0.0013). In the 90% of nodules that were managed nonoperatively, 63% had at least one surveillance US. Timing of initial surveillance US ranged from 3 to 60 months (median 13 months, interquartile [IQR] 11-19 months). Median follow-up duration was 25 months (IQR 17-34 months). Nodule growth occurred in 24% of nodules; only a minority (7%) underwent repeat FNA. Conclusions: Negative subtype of TSv3 should be considered in clinical management recommendations. For negative but limited samples, repeat FNA should be performed. Optimal surveillance strategy for nonresected negative and currently negative nodules remains unknown. Until further real-world data are available, surveillance ultrasonography is recommended for TSN and TSCN nodules, similar to the ATA guidelines for TBSRTC II nodules.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Nachum S, Tondi Resta I, Baloch Z, et al. Thyroid Nodules with Indeterminate Cytology and Negative Molecular Profile: Prevalence of Malignancy and Practice Paradigms for Surveillance. Thyroid. 2025. PMID: 39874551. doi:10.1089/thy.2024.0455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。